XBI - Bank of America more favorable on SMID-cap biotechs into 2024
2024-01-02 12:32:09 ET
More on COVID vaccine makers
- BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics
- Novavax: Do Not Expect A Turnaround In 2024
- BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline
- Moderna upgraded at Oppenheimer on commercial prospects
- Moderna expands U.S. market share for COVID vaccine
For further details see:
Bank of America more favorable on SMID-cap biotechs into 2024